Document:

Exhibit 10.2

        

        

      

      ARTEMIS THERAPEUTICS INC.

       

      UNSECURED PROMISSORY NOTE

       

      Principal Amount: USD $30,000

       

      Original Issuance Date: September 19, 2021

       

      FOR VALUE RECEIVED Artemis Therapeutics Inc., a Delaware corporation (the "Company"), promises to pay to Harmony (H.A.) Investments Ltd. ("Holder"),
        the principal amount of thirty thousand dollars (USD $30,000) together with all accrued but unpaid interest, or such lesser amount as shall equal the then outstanding principal amount hereof together with all accrued but unpaid interest thereon,
        payable on December 19, 2021 (the "Maturity Date").

      

      

      The following is a statement of the rights of the Holder of this promissory note (the "Note") and the conditions to which this Note is subject, and to which the Holder, by
        the acceptance of this Note, agrees:

       

      1.          Interest.

       

      (a)         Interest shall accrue on the original Principal Amount of this Note from the Original Issuance Date through the Maturity Date at the rate of ten percent (10%) per
        annum, except as set forth herein in connection with an Event of Default (as hereinafter defined).

      

      

      (b)         From and after the Maturity Date or upon the occurrence and during the continuance of an Event of Default (as hereinafter defined) that is not remedied within the
        applicable cure period, interest shall accrue on the unpaid principal balance during any such period at an annual rate equal to twelve percent (12%) plus the interest rate set forth in Section 1(a) herein ("Default Rate"), provided, however,
        in no event shall the Default Rate exceed the maximum rate permitted by law. The interest accruing under this subsection (b) shall be immediately due and payable by the Company to the Holder upon demand and shall be additional indebtedness
        evidenced by this Note.

      

      

      (c)          Interest on this Note shall be calculated on the basis of a 365-day year and the actual number of days elapsed in any portion of a month in which interest is due. If
        any payment to be made by the Company hereunder shall become due on a Saturday, Sunday or a legal holiday on which banks are authorized or required to be closed for the conduct of commercial banking business in the United States, such payment shall
        be made on the next succeeding business day and such extension of time shall be included in computing any interest in respect of such payment.

      

      

      (d)          Notwithstanding anything to the contrary contained herein, in no event shall this or any other provision herein permit the collection of any interest which would be
        usurious under applicable law.  If under any circumstances, whether by reason of advancement or acceleration of the maturity of the unpaid principal balance hereof or otherwise, the aggregate amounts paid under this Note shall include amounts which
        by law are deemed interest and which would exceed the maximum rate permitted by law, the Company stipulates that payment and collection of such excess amounts shall have been and will be deemed to have been the result of a mistake on the part of
        both Holder and the Company or the holder of this Note, and the party receiving such excess payments shall promptly credit such excess (only to the extent such payments are in excess of the maximum rate) against the unpaid principal balance hereof
        and any portion of such excess payments not capable of being so credited shall be refunded to the Company.

       

      
        
          

      

      
      2.          Event of Default.

       

      (a)          For purposes of this Note, an "Event of Default" means:

       

      (i)           the Company shall default in any payment of principal and/or accrued interest on this Note within ten (10) business days following the date upon
        which the relevant payment is due under this Note; or

       

      (ii)          the Company shall (a) become insolvent; (b) admit in writing its inability to pay its debts generally as they mature; (c) make an assignment for
        the benefit of creditors or commence proceedings for its dissolution; or (d) apply for or consent to the appointment of a trustee, liquidator, receiver or similar official for it or for a substantial part of its property or business; or

       

      (iii)          a trustee, liquidator or receiver shall be appointed for the Company or for a substantial part of its property or business without its consent
        and shall not be discharged within sixty (60) days after such appointment; or

       

      (iv)          any governmental agency or any court of competent jurisdiction at the insistence of any governmental agency shall assume custody or control of
        the whole or any substantial portion of the properties or assets of the Company and shall not be dismissed within sixty (60) days thereafter; or

       

      (v)          bankruptcy, reorganization, insolvency or liquidation proceedings or other proceedings, or relief under any bankruptcy law or any law for the
        relief of debt shall be instituted by or against the Company and, if instituted against the Company shall not be dismissed within sixty (60) days after such institution, or the Company shall by any action or answer approve of, consent to, or
        acquiesce in any such proceedings or admit to any material allegations of, or default in answering a petition filed in any such proceeding.

       

      (b)          Upon the occurrence of an Event of Default, the entire unpaid and outstanding indebtedness due under this Note shall be immediately due and
        payable following notice by the Holder (save for an Event of Default under sub-section (iii) or under subsection (v) if instituted by the Company, in which such case no prior notice will be required), and the Holder shall be able to undertake any
        and all remedies available to it under this Note and applicable law.

       

      (c)          As soon as possible and in any event within two business days after the Company becomes aware that an Event of Default has occurred, the Company
        shall notify the Holder in writing of the nature, extent and time of and the facts surrounding such Event of Default, and the action, if any, that the Company proposes to take with respect to such Event of Default.

       

      
        2

        
          

      

      3.              Miscellaneous.

       

          (a)          Loss, Theft, Destruction or Mutilation of Note.  Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or
        mutilation of this Note and delivery of an indemnity agreement reasonably satisfactory in form and substance to the Company and, in the case of mutilation, on surrender and cancellation of this Note (or what remains thereof), the Company shall
        execute and deliver, in lieu of this Note, a new note executed in the same manner as this Note, in the same principal amount as the unpaid principal amount of this Note and dated the date of this Note.

       

        (b)          Payment.  All payments under this Note shall be made in United States Dollars no later than 5:30 pm, Eastern Time, on the date on which such payment is
        due, by wire transfer of immediately available funds to the account identified by the Holder.

       

      (c)          Waivers.  The Company hereby waives notice of default, presentment or demand for payment, protest or notice of nonpayment or dishonor and
        all other notices or demands relative to this instrument.

       

      (d)          Waiver and Amendment.  Any provision of this Note may be amended, waived or modified only by an instrument in writing signed by the party
        against which enforcement of the same is sought.

       

      (e)          Notices.  All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in
        writing and, unless otherwise specified herein, shall be (i) personally served or (ii) transmitted by hand delivery, addressed as set forth below or to such other address as such party shall have specified most recently by written notice.  Any
        notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery at the address or number designated below (if delivered on a business day during normal business hours where such notice is
        to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by
        express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.  The addresses for such communications shall be:

      

      

      If to the Company, to:

      

      

      Artemis Therapeutics Inc.

      18 East 16th Street, Suite 307

      New York, NY 10003

      Attention: Chief Financial Officer

      

      

      If to the Holder: Harmony (H.A.) Investments Ltd.

             1 HaHarouv Street, Ramat Hasharon, Israel

      

      

      
        3

        
          

      

      (f)           Expenses; Attorneys’ Fees.  If action is instituted to enforce or collect this Note, the Company undertakes to pay or reimburse all
        reasonable costs and expenses, including, without limitation, reasonable attorneys’ fees and costs, incurred by the Holder in connection with such action.

       

      (g)          Successors and Assigns.  This Note may be assigned or transferred by the Holder with the written consent of the Company, and this Note
        may be assigned or transferred by the Company with the written consent of the Holder.  Subject to the preceding sentence, the rights and obligations of the Company and the Holder of this Note shall be binding upon and benefit the successors,
        permitted assigns, heirs, administrators and permitted transferees of the parties.  Upon assignment hereof, in whole or in part, the Company shall execute and deliver, in lieu of this Note, a new note or notes executed in the same manner as this
        Note, in the same principal amounts as the unpaid principal amounts of this Note as so assigned, or retained, as the case may be, dated the date of such assignment.

       

      (h)          No Waiver; Cumulative Remedies. No failure to exercise and no delay in exercising on the part of either party, any right, option,
        remedy, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right, option, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other
        right, option, remedy, power or privilege.  The rights, options, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, options, remedies, powers and privileges provided by law.

       

      (i)          Severability.  If any term or other provision of this Note is invalid, illegal or incapable of being enforced by any rule of law, or
        public policy, all other conditions and provisions of this Note shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any
        party.  Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Note so as to effect the original intent of the parties as closely
        as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible.

       

      (i)           Construction.  Each party hereto acknowledges and agrees it has had the opportunity to draft, review, and edit the language of this
        Note and that no presumption for or against any party arising out of drafting all or any part of this Note will be applied in any dispute relating to, in connection with, or involving this Note.  Accordingly, the parties hereto hereby waive the
        benefit of any rule of law or any legal decision that would require, in cases of uncertainty, that the language of a contract should be interpreted most strongly against the party who drafted such language.

       

      (j)           Governing Law; Jurisdiction.  This Note shall be governed by and construed in accordance with the laws of the State of New York without
        regard to principles of conflicts of laws. The parties to this Note irrevocably submit to the exclusive jurisdiction of the competent courts of the State of New York for the purpose of any suit, action, proceeding or judgment relating to or arising
        out of this Note and the transactions contemplated hereby. The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction
        or venue or based upon forum non-conveniens.  THE COMPANY AND HOLDER WAIVE TRIAL BY JURY.  The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs.  Each party hereby irrevocably waives
        personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
        party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
        serve process in any other manner permitted by law.

       

      [Signature page follows]

      

      

      
        4

        
          

      

      IN WITNESS WHEREOF, the Company has caused this Note to be executed as of the date first above written by its duly authorized officer.

       

      
        	 	
                ARTEMIS THERAPEUTICS INC.

              	 
	 	 	 	 
	
                

                

              	
                By: 

              	/s/ Chanan Morris	 
	 	Name:

                	Chanan Morris	 
	 	Title:	CFO

              	 

      

       

      [Company signature page to Promissory Note]

       

      
        5

        
          

      

      Receipt acknowledged:

       

      Name of Holder:

       

      Harmony (H.A.) Investments Ltd.

       

      By: /s/ Reut Alfiah

      Name: Reut Alfiah

      Title: Director

       

      [Holder signature page to Promissory Note]

      

      

    

  

  6Exhibit 4.7

    

    

    RIGHTS AGREEMENT

    

    

    This Rights Agreement (this “Agreement”) is made as of __________, 2021, by and between bleuacacia ltd, a  Cayman Islands exempted company
      (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Rights Agent”).

    

    

    WHEREAS, the Company is engaged in a public offering (the “Public Offering”) of 20,000,000 units (the “Units”) of the Company (and up to 3,000,000 additional Units if the underwriters’ over-allotment option is exercised in full), each Unit consisting of one Class A ordinary share of the Company, par value $0.0001 per
      share (the “Ordinary Shares”), one right to receive one-sixteenth of one Ordinary Share upon the happening of the triggering event described herein (the “Right”), and one warrant to purchase one half of an Ordinary Share (the “Warrant”);

    

    

    WHEREAS, the Company has filed with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form S-1, File No.
      333-257240 (the “Registration Statement”), and related Prospectus (the “Prospectus”) for the registration, under the Securities
      Act of 1933, as amended (the “Securities Act”), of, among other securities, the Rights and the Ordinary Shares issuable to the holders of the Rights;

    

    

    WHEREAS, the Company desires the Rights Agent to act on behalf of the Company, and the Rights Agent is willing to so act, in connection with the issuance, registration, transfer and exchange of the
      Rights;

    

    

    WHEREAS, the Company desires to provide for the form and provisions of the Rights, the terms upon which they shall be issued, and the respective rights, limitation of rights, and immunities of the
      Company, the Rights Agent, and the holders of the Rights; and

    

    

    WHEREAS, all acts and things have been done and performed which are necessary to make the Rights, when executed on behalf of the Company and countersigned by or on behalf of the Rights Agent, as
      provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Agreement.

    

    

    NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

    

    

    1.           Appointment of Rights Agent. The Company hereby appoints the Rights Agent to act as agent for the Company for the Rights, and the Rights Agent hereby accepts such appointment and
      agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.

    

    

    2.            Rights.

    

    

    2.1         Form of Right. Each Right shall be issued in registered form only, shall be in substantially the form of Exhibit A hereto, the provisions of which are incorporated herein
      and shall be signed by, or bear the facsimile signature of, a Co-Chairman of the Board, a Co-Chief Executive Officer, the Chief Financial Officer or the Executive Director of the Company. In the event the person whose facsimile signature has been
      placed upon any Right shall have ceased to serve in the capacity in which such person signed the Right before such Right is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.

    

    

    2.2          Effect of Countersignature. Unless and until countersigned by the Rights Agent pursuant to this Agreement, a Right shall be invalid and of no effect and may not be exchanged for
      Ordinary Shares.

    

    

    2.3          Registration.

    

    

    2.3.1      Right Register. The Rights Agent shall maintain books (the “Right Register”) for the registration of original issuance
      and the registration of transfer of the Rights. Upon the initial issuance of the Rights, the Rights Agent shall issue and register the Rights in the names of the respective holders thereof in such denominations and otherwise in accordance with
      instructions delivered to the Rights Agent by the Company.

    

    

    
      
        

    

    
    2.3.2      Registered Holder. Prior to due presentment for registration of transfer of any Right, the Company and the Rights Agent may deem and treat the person in whose name such Right
      shall be registered upon the Right Register (the “Registered Holder”) as the absolute owner of such Right and of each Right represented thereby (notwithstanding any notation of ownership or
      other writing on the Right Certificate made by anyone other than the Company or the Rights Agent), for the purpose of the exchange thereof, and for all other purposes, and neither the Company nor the Rights Agent shall be affected by any notice to
      the contrary.

    

    

    2.4         Detachability of Rights. Each of the securities comprising the Units shall begin separate trading on the fifty-second (52nd) day following the date of the
      Prospectus or, if such fifty-second (52nd) day is not on a day other than a Saturday, Sunday or federal holiday on which banks in New York City are generally open for normal business (a “Business
        Day”), then on the immediately succeeding Business Day following such date, or earlier (the “Detachment Date”) with the consent of Credit Suisse Securities (USA) LLC and Citigroup
      Global Markets Inc. with the respect to such consent, but in no event shall the securities comprising the Units be separately traded until (A) the Company has filed a Current Report on Form 8-K with the SEC containing an audited balance sheet
      reflecting the receipt by the Company of the gross proceeds of the Offering, including the proceeds received by the Company from the exercise by the underwriters of their right to purchase additional Units in the Offering (the “Over-Allotment Option”), if the Over-Allotment Option is exercised prior to the filing of such Form 8-K, and a second or amended Current Report on Form 8-K to provide updated financial
      information to reflect the exercise of the underwriters’ Over-Allotment option, if the Over-Allotment option is exercised following the initial filing of such Current Report on Form 8-K, and (B) the Company issues a press release and files with the
      Commission a Current Report on Form 8-K announcing when such separate trading shall begin. Upon the Detachment Date, holders of Units will have the option to continue to hold Units or separate their Units into the component pieces.

    

    

    3.            Terms and Exchange of Rights

    

    

    3.1         Rights. Each Right shall entitle the holder thereof to receive one-sixteenth of one Ordinary Share upon the happening of an Exchange Event (defined below). No additional
      consideration shall be paid by a holder of Rights in order to receive his, her or its Ordinary Shares upon an Exchange Event as the purchase price for such Ordinary Shares has been included in the purchase price for the Units. In no event will the
      Company be required to net cash settle the Rights or issue fractional Ordinary Shares.

    

    

    3.2          Exchange Event. An “Exchange Event” shall occur upon the Company’s consummation of an initial Business Combination (as
      defined in the Company’s Amended and Restated Memorandum and Articles of Association).

    

    

    3.3          Exchange of Rights.

    

    

    3.3.1      Issuance of Ordinary Shares. As soon as practicable upon the occurrence of an Exchange Event, the Company shall direct holders of the Rights to return their Rights Certificates to
      the Rights Agent. Upon receipt of a valid Rights Certificate, the Company shall issue to the Registered Holder of such Right(s) the number of full Ordinary Shares to which he, she or it is entitled, registered in such name or names as may be directed
      by him, her or it and issue to such Registered Holder(s) a certificate or book-entry position for the such shares. Notwithstanding the foregoing, or any provision contained in this Agreement to the contrary, in no event will the Company be required
      to net cash settle the Rights. The Company shall not issue fractional shares upon exchange of Rights. In the event that any holder would otherwise be entitled to any fractional share upon exchange of Rights, at the time of an Exchange Event, the
      Company will instruct the Right Agent how any such entitlement will be addressed. To the fullest extent permitted by the Company’s Amended and Restated Memorandum and Articles of Association the Company reserves the right to deal with any such
      fractional entitlement at the relevant time in any manner permitted by the Securities Act and the Amended and Restated Memorandum and Articles of Association, which would include the rounding down of any entitlement to receive Ordinary Shares to the
      nearest whole share (and in effect extinguishing any fractional entitlement), or the holder being entitled to hold any remaining fractional entitlement (without any share being issued) and to aggregate the same with any future fractional entitlement
      to receive shares in the Company until the holder is entitled to receive a whole number. Any rounding down and extinguishment may be done with or without any in lieu cash payment or other compensation being made to the holder of the relevant Rights,
      such that value received on exchange of the Rights may be considered less than the value that the holder would otherwise expect to receive.

    

    

    
      2

      
        

    

    3.3.2      Valid Issuance. All Ordinary Shares issued upon an Exchange Event in conformity with this Agreement shall be validly issued, fully paid and nonassessable.

    

    

    3.3.3      Date of Issuance. Each person in whose name any such certificate or book-entry position for Ordinary Shares is issued shall for all purposes be deemed to have become the holder of
      record of such shares on the date of the Exchange Event, irrespective of the date of delivery of such certificate or entry of position.

    

    

    
      
        3.3.4       Company Not Surviving Following Exchange Event. Upon an Exchange Event in which the Company does not continue as the publicly held reporting entity, the definitive agreement
          will provide for the holders of Rights to receive the same per share consideration the holders of the Ordinary Shares will receive in such transaction, for the number of shares such holder is entitled to pursuant to Section 3.3.1
          above. If the Company does not continue as the publicly held reporting entity upon an Exchange Event, each holder of a Right will be required to affirmatively convert his/her or its rights in order to receive the one-sixteenth of one share
          underlying each right (without paying any additional consideration) upon consummation of the Exchange Event. In such a case, each holder of a Right will be required to indicate his, her or its election to convert the Rights into underlying
          Ordinary Shares as well as to return the original certificates evidencing the Rights to the Company.

      

    

    

    

    3.4        Duration of Rights. If an Exchange Event does not occur within the time period set forth in the Company’s Amended and Restated Memorandum and Articles of Association, as the same
      may be amended from time to time, the Rights shall expire and shall be worthless.

    

    

    4.            Transfer and Exchange of Rights.

    

    

    4.1        Registration of Transfer. The Rights Agent shall register the transfer, from time to time, of any outstanding Right upon the Right Register, upon surrender of such Right for
      transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Right representing an equal aggregate number of Rights shall be issued and the old Right shall be
      cancelled by the Rights Agent. The Rights so cancelled shall be delivered by the Rights Agent to the Company from time to time upon request.

    

    

    4.2         Procedure for Surrender of Rights. Rights may be surrendered to the Rights Agent, together with a written request for exchange or transfer, and thereupon the Rights Agent shall
      issue in exchange therefor one or more new Rights as requested by the Registered Holder of the Rights so surrendered, representing an equal aggregate number of Rights; provided, however, that in the event that a Right surrendered for transfer bears a
      restrictive legend and the new Rights to be issued will not bear a restrictive legend, the Rights Agent shall not cancel such Right and issue new Rights in exchange therefor until the Rights Agent has received an opinion of counsel for the Company
      stating that such transfer may be made and indicating no restrictive legend is required.

    

    

    4.3         Fractional Rights. The Rights Agent shall not be required to effect any registration of transfer or exchange which will result in the issuance of a Right Certificate for a
      fraction of a Right.

    

    

    4.4          Service Charges. No service charge shall be made for any exchange or registration of transfer of Rights.

    

    

    4.5         Adjustments to Conversion Ratios. The number of Ordinary Shares that the holders of Rights are entitled to receive as a result of the occurrence of an Exchange Event shall be
      equitably adjusted to reflect appropriately the effect of any share split, reverse share split, share dividend, reorganization, recapitalization, reclassification, combination, exchange of shares or other like change with respect to the Ordinary
      Shares occurring on or after the date hereof and prior to the Exchange Event.

    

    

    
      3

      
        

    

    4.6         Right Execution and Countersignature. The Rights Agent is hereby authorized to countersign and to deliver, in accordance with the terms of this Agreement, the Rights required to
      be issued pursuant to the provisions of this Section 4, and the Company, whenever required by the Rights Agent, will supply the Rights Agent with Rights duly executed on behalf of the Company for such purpose.

    

    

    5.          Other Provisions Relating to Rights of Holders of Rights.

    

    

    5.1         No Rights as Shareholder. Until the exchange of a Right for Ordinary Shares as provided for herein, a Right does not entitle the Registered Holder thereof to any of the rights of
      a shareholder of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent or to receive notice as shareholders in respect of the meetings of shareholders
      or the election of directors of the Company or any other matter.

    

    

    5.2         Lost, Stolen, Mutilated, or Destroyed Rights. If any Right is lost, stolen, mutilated, or destroyed, the Company and the Rights Agent may on such terms as to indemnity or
      otherwise as they may in their discretion impose (which shall, in the case of a mutilated Right, include the surrender thereof), issue a new Right of like denomination, tenor, and date as the Right so lost, stolen, mutilated, or destroyed. Any such
      new Right shall constitute a substitute contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated, or destroyed Right shall be at any time enforceable by anyone.

    

    

    5.3          Reservation of Ordinary Shares. The Company shall at all times reserve and keep available a number of its authorized but unissued Ordinary Shares that will be sufficient to
      permit the exchange of all outstanding Rights issued pursuant to this Agreement.

    

    

    6.          Concerning the Rights Agent and Other Matters.

    

    

    6.1          Payment of Taxes. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Rights Agent in respect of the issuance or
      delivery of Ordinary Shares upon the exchange of Rights, but the Company shall not be obligated to pay any transfer taxes in respect of the Rights or such Ordinary Shares.

    

    

    6.2          Resignation, Consolidation, or Merger of Rights Agent.

    

    

    6.2.1      Appointment of Successor Rights Agent. The Rights Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and
      liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office of the Rights Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Rights Agent in
      place of the Rights Agent. If the Company shall fail to make such appointment within a period of 30 days after it has been notified in writing of such resignation or incapacity by the Rights Agent or by the holder of the Right (who shall, with such
      notice, submit his, her or its Right for inspection by the Company), then the holder of any Right may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Rights Agent at the Company’s
      cost. Any successor Rights Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan,
      City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor Rights Agent shall be vested with all the
      authority, powers, rights, immunities, duties, and obligations of its predecessor Rights Agent with like effect as if originally named as Rights Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or
      appropriate, the predecessor Rights Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Rights Agent all the authority, powers, and rights of such predecessor Rights Agent hereunder; and upon
      request of any successor Rights Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Rights Agent all such authority, powers,
      rights, immunities, duties, and obligations.

    

    

    
      4

      
        

    

    6.2.2      Notice of Successor Rights Agent. In the event a successor Rights Agent shall be appointed, the Company shall give notice thereof to the predecessor Rights Agent and the transfer
      agent for the Ordinary Shares not later than the effective date of any such appointment.

    

    

    6.2.3      Merger or Consolidation of Rights Agent. Any corporation into which the Rights Agent may be merged or with which it may be consolidated or any corporation resulting from any
      merger or consolidation to which the Rights Agent shall be a party shall be the successor Rights Agent under this Agreement without any further act.

    

    

    
      
        6.3          Fees and Expenses of Rights Agent.

      

    

    

    

    6.3.1      Remuneration. The Company agrees to pay the Rights Agent reasonable remuneration for its services as such Rights Agent hereunder and will reimburse the Rights Agent upon demand
      for all expenditures that the Rights Agent may reasonably incur in the execution of its duties hereunder.

    

    

    6.3.2      Further Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged, and delivered all such further and other
      acts, instruments, and assurances as may reasonably be required by the Rights Agent for the carrying out or performing of the provisions of this Agreement.

    

    

    6.4          Liability of Rights Agent.

    

    

    6.4.1     Reliance on Company Statement. Whenever in the performance of its duties under this Agreement, the Rights Agent shall deem it necessary or desirable that any fact or matter be
      proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a
      statement signed by the Chief Executive Officer or Chief Financial Officer and delivered to the Rights Agent. The Rights Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this
      Agreement.

    

    

    6.4.2      Indemnity. The Rights Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. Subject to Section 6.6 below, the Company
      agrees to indemnify the Rights Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel fees, for anything done or omitted by the Rights Agent in the execution of this Agreement except as a result
      of the Rights Agent’s gross negligence, willful misconduct, or bad faith.

    

    

    6.4.3     Exclusions. The Rights Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution of any Right (except its
      countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Right; nor shall it by any act hereunder be deemed to make any representation or warranty as to
      the authorization or reservation of any Ordinary Shares to be issued pursuant to this Agreement or any Right or as to whether any Ordinary Shares will when issued be valid and fully paid and nonassessable.

    

    

    6.5          Acceptance of Agency. The Rights Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms and conditions herein set forth.

    

    

    6.6         Waiver. The Rights Agent hereby waives any right of set-off or any other right, title, interest or claim of any kind (“Claim”)

      in, or to any distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date hereof, by and between the Company and the Rights Agent as trustee thereunder) and hereby agrees not to seek
      recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever.

    

    

    
      5

      
        

    

    7.           Miscellaneous Provisions.

    

    

    7.1          Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Rights Agent shall bind and inure to the benefit of their respective
      successors and assigns.

    

    

    7.2         Notices. Any notice, statement or demand authorized by this Agreement to be given or made by the Rights Agent or by the holder of any Right to or on the Company shall be
      sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the
      Company with the Rights Agent), as follows:

    

    

    bleuacacia ltd

    500 Fifth Avenue

    New York, New York 10110

    Attention: Co-Chief Executive Officers

    

    

    with a copy (which shall not constitute notice) to:

    

    

    Freshfields Bruckhaus Deringer US LLP

    601 Lexington Avenue

    New York, New York 10022

    Attention: Valerie Ford Jacob, Esq.

    Email: valerie.jacob@freshfields.com

    

    

    Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Right or by the Company to or on the Rights Agent shall be sufficiently given when so delivered
      if by hand or overnight delivery or if sent by certified mail or private courier service within five days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Rights Agent with the Company), as
      follows:

    

    

    Continental Stock Transfer & Trust Company

    One State Street, 30th Floor

    New York, New York 10004

    Attn: Compliance Department

    

    

    in each case, with a copy to:

    

    

    [●]

    

    

    7.3          Applicable Law and Exclusive Forum. The validity, interpretation, and performance of this Agreement and of the Rights shall be governed in all respects by the laws of the State
      of New York, without giving effect to conflict of laws. Subject to applicable law, the Company and the Rights Agent hereby agree that any action, proceeding or claim against either of them arising out of or relating in any way to this Agreement shall
      be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive forum for any such action,
      proceeding or claim. The Company and the Rights Agent hereby waive any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Notwithstanding the foregoing, the provisions of this paragraph will not apply to
      suits brought to enforce (i) any liability or duty created by the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or the rules
      and regulations thereunder for which Section 27 of the Exchange Act creates exclusive federal jurisdiction, (ii) with respect to suits brought in federal courts, any duty or liability created by the Securities Act or the rules and regulations
      thereunder for which Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts or (iii) any other claim for which the federal district courts of the United States of America are the sole and exclusive forum.

    

    

    
      6

      
        

    

    Any person or entity purchasing or otherwise acquiring any interest in the Rights shall be deemed to have notice of and to have consented to the forum provisions in this Section 7.3.
      If any action, the subject matter of which is within the scope the forum provisions above, is filed in a court other than a court located within the State of New York or the United States District Court for the Southern District of New York (a “foreign action”) in the name of any Rights holder, such Rights holder shall be deemed to have consented to: (x) the personal jurisdiction of the state and federal courts located within the State
      of New York or the United States District Court for the Southern District of New York in connection with any action brought in any such court to enforce the forum provisions (an “enforcement action”),

      and (y) having service of process made upon such Rights holder in any such enforcement action by service upon such Rights holder’s counsel in the foreign action as agent for such Rights holder.

    

    

    7.4         Persons Having Rights under this Agreement. Nothing in this Agreement expressed and nothing that may be implied from any of the provisions hereof is intended, or shall be
      construed, to confer upon, or give to, any person or corporation other than the parties hereto and the Registered Holders of the Rights and any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation,
      promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the Registered
      Holders of the Rights.

    

    

    7.5          Examination of the Right Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Rights Agent in the Borough of Manhattan, City and
      State of New York, for inspection by the Registered Holder of any Right. The Rights Agent may require any such holder to submit his, her or its Right for inspection by it.

    

    

    7.6         Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original,
      and all such counterparts shall together constitute but one and the same instrument.

    

    

    7.7          Effect of Headings. The Section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof.

    

    

    7.8         Amendments. This Agreement may be amended by the parties hereto without the consent of any Registered Holder for the purpose of curing any ambiguity, or of curing, correcting or
      supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that the parties deem shall not
      adversely affect the interest of the Registered Holders. All other modifications or amendments shall require the written consent or vote of the Registered Holders of a majority of the then outstanding Rights.

    

    

    7.9         Severability. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of
      this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to
      such invalid or unenforceable provision as may be possible and be valid and enforceable.

    

    

    [Signature Page Follows]

    

    

    
      7

      
        

    

    IN WITNESS WHEREOF, this Agreement
        has been duly executed by the parties hereto as of the day and year first above written.

    

    

    

    

    	 	
            BLEUACACIA LTD

          
	 	
            By:

          	 	 
	 	 	
            Name:

          	 
	 	 	
            Title:

          	 

    

    

    

    
      	 	
              CONTINENTAL STOCK TRANSFER & TRUST COMPANY

            
	 	
              By:

            	 	 
	 	 	
              Name:

            	 
	
               

            	 	
              Title:

            	 

    

    

    

    

      [Signature Page to Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]